Mercado de diagnóstico de cancro do pulmão de células não pequenas da América do Norte – Tendências do setor e previsão para 2028

Análise de mercado e insights: Mercado de diagnóstico de cancro do pulmão de células não pequenas da América do Norte

Espera-se que o mercado de diagnóstico de cancro do pulmão de células não pequenas da América do Norte ganhe crescimento de mercado no período de previsão de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 13, 0% no período de previsão de 2021 a 2028. e deverá atingir 1.440,42 milhões de dólares até 2028.

O cancro do pulmão de células não pequenas é uma doença na qual se formam células malignas ou cancerígenas nos tecidos dos pulmões. São de tipos diferentes e cada tipo tem células cancerígenas diferentes que crescem e se espalham de formas diferentes. O tipo de cancro do pulmão de células não pequenas (CPCNP) é o carcinoma de células escamosas, o carcinoma de células grandes e o adenocarcinoma. No carcinoma de células escamosas, o cancro forma-se nas células finas e planas que revestem o interior dos pulmões e também são chamados de carcinoma epidermóide, o cancro de carcinoma de células grandes começa em vários tipos de células grandes e o tipo de cancro de adenocarcinoma inicia-se nas células que revestem os alvéolos e produzir substâncias como o muco. Um dos principais riscos para o cancro do pulmão de células não pequenas (CPCNP) é o tabagismo e os sintomas incluem tosse, que não desaparece, e falta de ar. São utilizados vários testes, como exames de imagem, testes moleculares, biópsia e outros, para diagnosticar e examinar o estádio do cancro. O diagnóstico é importante para identificar a doença a tempo para que possa ser administrado o tratamento adequado

Os fatores que impulsionam o crescimento do mercado de diagnóstico do cancro do pulmão de células não pequenas são a utilização do aumento do número da população idosa que é mais suscetível ao cancro do pulmão de células não pequenas, enquanto a elevada concorrência no mercado entre os players locais e globais pode conter o crescimento do mercado de diagnóstico do cancro do pulmão de células não pequenas.

O relatório de mercado de diagnóstico de cancro do pulmão de células não pequenas fornece detalhes de quota de mercado, novos desenvolvimentos e análise de pipeline de produtos, impacto dos participantes do mercado doméstico e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, mudanças nas regulamentações de mercado, aprovações de produtos, estratégias decisões, lançamentos de produtos, expansões geográficas e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado de logística de visão de máquina, contacte a Data Bridge Market Research para obter um resumo do analista, a nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir o objetivo desejado.

Âmbito e dimensão do mercado de diagnóstico de cancro do pulmão de células não pequenas da América do Norte

The North America non-small cell lung cancer diagnostics market is segmented into four notable segments based on the lung cancer type, product, test and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of cancer type, the North America non-small cell lung cancer diagnostics market is segmented into lung adenocarcinoma (LUAD), lung squamous cellcarcinoma (LUSC), large cell carcinoma and others. In 2021, the lung adenocarcinoma (LUAD) segment is expected to dominate the non-small cell lung cancer diagnostics market due to the high prevalence of the Lung Adenocarcinoma among all type of non-small cell lung cancer.
• On the basis of product, the North America non-small cell lung cancer diagnostics market is segmented into reagents & kits, instruments and services & softwares. In 2021, the instrument segment is expected to dominate the non-small cell lung cancer diagnostics market due to the availability of the instrument along with advancement in the technology.
• On the basis of test, the North America non-small cell lung cancer diagnostics market is segmented imaging test, molecular test, biopsy, sputum cytology, thoracentesis, immunohistochemistry and others. In 2021, the molecular test segment is expected to dominate the non-small cell lung cancer diagnostics market due to rising need of molecular tests to diagnose non-small cell lung cancer accurately and efficiently.
• On the basis of end user, the North America non-small cell lung cancer diagnostics market is segmented into hospital, clinical laboratories, academics and others. In 2021, the clinical laboratories segment is expected to dominate the non-small cell lung cancer diagnostics market due to the growing clinical research in cancer.

North America Non-Small Cell Lung Cancer Diagnostics Market: Country Level Analysis

North America non-small cell lung cancer diagnostics market is analyzed and market size information is provided by country, lung cancer type, products, test and end user.

Countries covered in the North America Non-small cell lung cancer diagnostics market report are US, Canada and Mexico.

US is dominating the non-small cell lung cancer diagnostics market with the highest CAGR and highest market share due to growing cases of cancer in U.S.

In U.S., Lung Adenocarcinoma (LUAD) segment is growing due to high prevalence of lung adenocarcinoma among types of non-small cell lung cancer. In Canada, the Lung Adenocarcinoma (LUAD) segment is growing due to rise in need for molecular tests to diagnose non-small cell lung cancer accurately. In Mexico, the Lung Adenocarcinoma (LUAD) segment is growing due to advancements made in technology used in the clinical laboratory to detect molecular abnormalities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Rising Demand of Diagnostic in Medical Setting

North America non-small cell lung cancer diagnostics market also provides you with detailed market analysis for every country growth in industry with sales, components sales, impact of technological development in non-small cell lung cancer diagnostics, and changes in regulatory scenarios with their support for the non-small cell lung cancer diagnostics market. The data is available for historic period 2010 to 2019.

Competitive Landscape and North America Non-Small Cell Lung Cancer Diagnostics Market Share Analysis

North America non-small cell lung cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, India presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, and technology lifeline curve. The above data points provided are only related to the companies’ focus related to non-small cell lung cancer diagnostics market.

Some of the major players operating in the non-small cell lung cancer diagnostics market are Abbott, F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., QIAGEN, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., NanoString, Janssen Pharmaceutical NV, Inivata Ltd, bioMérieux SA, Biotheranostics, OncoCyte Corporation Inc., GENERAL ELECTRIC COMPANY, Eckert & Ziegler, DrLal PathLabs, RIVERAIN TECHNOLOGIES, PlexBio Co.,Ltd, Oncimmune, and Biodesix among others.

North America non-small cell lung cancer diagnostics market is fragmented and the major players have used various strategies such as collaborations, recognitions, agreements, and others, to increase their footprints in the non-small cell lung cancer diagnostics market.

For instance,

• In March 2021, Agilent Technologies, Inc. acquired Resolution Bioscience for USD 550 million to strengthen its business in next-generation sequencing (NGS)-based oncology solutions
• In May 2021, QIAGEN launched FDA approved therascreen KRAS RGQ PCR Kit, which aids in the identification of non-small cell lung cancer (NSCLC) in patients
• Em junho de 2020, a F. Hoffmann-La Roche Ltd lançou o algoritmo automatizado de patologia digital, análise de imagem uPath PD-L1 (SP263) para diagnosticar o cancro do pulmão de células não pequenas (CPCNP) e melhorar a velocidade e precisão do tratamento diagnóstico

SKU-64358